Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
AstraZeneca
Merck
Harvard Business School
Dow

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OSPEMIFENE

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for OSPEMIFENE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00276094 ↗ A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women Completed Hormos Medical Phase 3 2006-01-01 The purpose of this study is to determine whether ospemifene is more effective than placebo in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women.
NCT00276094 ↗ A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women Completed QuatRx Pharmaceuticals Phase 3 2006-01-01 The purpose of this study is to determine whether ospemifene is more effective than placebo in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women.
NCT00276094 ↗ A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women Completed Shionogi Phase 3 2006-01-01 The purpose of this study is to determine whether ospemifene is more effective than placebo in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women.
NCT00566982 ↗ A Clinical Study to Evaluate the Safety of Ospemifene Completed Hormos Medical Phase 3 2007-10-01 The purpose of this study is to determine the efficacy and long-term safety of 60mg ospemifene in the treatment of VVA in postmenopausal women with intact uterus.
NCT00566982 ↗ A Clinical Study to Evaluate the Safety of Ospemifene Completed QuatRx Pharmaceuticals Phase 3 2007-10-01 The purpose of this study is to determine the efficacy and long-term safety of 60mg ospemifene in the treatment of VVA in postmenopausal women with intact uterus.
NCT00566982 ↗ A Clinical Study to Evaluate the Safety of Ospemifene Completed Shionogi Phase 3 2007-10-01 The purpose of this study is to determine the efficacy and long-term safety of 60mg ospemifene in the treatment of VVA in postmenopausal women with intact uterus.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for OSPEMIFENE

Condition Name

Condition Name for OSPEMIFENE
Intervention Trials
Vaginal Diseases 6
Atrophy 6
Vaginal Dryness 1
Vulvovaginal Atrophy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for OSPEMIFENE
Intervention Trials
Atrophy 7
Vaginal Diseases 6
Disease 1
Sexual Dysfunction, Physiological 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for OSPEMIFENE

Trials by Country

Trials by Country for OSPEMIFENE
Location Trials
United States 31
Spain 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for OSPEMIFENE
Location Trials
Georgia 2
California 2
Massachusetts 1
Michigan 1
Montana 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for OSPEMIFENE

Clinical Trial Phase

Clinical Trial Phase for OSPEMIFENE
Clinical Trial Phase Trials
Phase 4 3
Phase 3 6
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for OSPEMIFENE
Clinical Trial Phase Trials
Completed 8
Recruiting 1
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for OSPEMIFENE

Sponsor Name

Sponsor Name for OSPEMIFENE
Sponsor Trials
Shionogi 7
QuatRx Pharmaceuticals 6
Hormos Medical 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for OSPEMIFENE
Sponsor Trials
Industry 17
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Baxter
McKinsey
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.